Benzinga · Aug 17, 2026
Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target
Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and maintains $8 price target.
MD
NASDAQ · MDXG
MiMedx Group, Inc.
Healthcare · Biotechnology
$4.33
Up+$0.03 (+0.70%)
Updated Aug 22, 2026, 1:42 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.06B
- P/E ratio
- 26
- Dividend yield
- 0.00%
- 52-week range
- $3.03 – $4.71
- Volume
- 897.11K
- Avg. volume
- 834.24K
Price performance
MDXG price history
1M range · 0 trading sessions · Daily adjusted prices
MDXG does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest MDXG news
The latest Smart Investors Daily articles mentioning MDXG.
Stock researchCompany · Overview
MDXG research
Overview
Company profile and research snapshot.
Company profile
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $11.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Cantor Fitzgerald | Overweight | — |
| Apr 30, 2026 | Citizens | Market Outperform | — |
| Apr 20, 2026 | Citizens | Market Outperform | — |
| Apr 17, 2026 | Craig-Hallum | Buy | — |
| Feb 23, 2026 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jul 30, 2026
MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript
MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call July 29, 2026 4:30 PM EDTCompany ParticipantsMatthew Notarianni - Head of Investor RelationsJoseph Capper -...
Yahoo · Jul 29, 2026
MiMedx Group Q2 Earnings Call Highlights
MiMedx Group (NASDAQ:MDXG) said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx’s second-quarter results, which showed sequential improvement in its wound-care busines
ChartMill · Jul 29, 2026
MIMEDX Group (NASDAQ:MDXG) Shares Fall After Q2 Revenue and EPS Slightly Miss Estimates
MIMEDX reported Q2 revenue of $64.4M, just below estimates, and a slight EPS miss, sending shares down 5.7% after-hours amid acquisition plans for Sanara MedTech.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
